A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions
- 15 Mar 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2020.
- 15 Mar 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2019.
- 04 Sep 2014 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.